HIV drugs

Payers can predict budget implications of high-cost drugs in the pipelineA University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.
Specialty drug pipeline predictions: Seven key areas to watchThe specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Non-adherence has big impact on Medicaid beneficiaries with HIVNew data presented at the International AIDS Society Conference examines the medical and financial burden of missing pills.
HIV dual therapy shows promiseA dual-drug regiment to treat HIV could soon be a reality, according to results presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Opinion: 3 steps health plans can take to end the HIV epidemicWe have a path to ending the HIV epidemic in the United States, but it requires health plans and healthcare purchasers to take a more active role in getting us there.
Multidrug-resistant HIV drug on the horizonAfter a successful phase 3 study, a breakthrough therapy to treat multi-drug resistant (MDR) HIV-1 is expected to launch in the United States in 2017.
Top 7 facts to know about new HIV drugFDA has approved Odefsey (Gilead Sciences, Inc.) for the treatment of HIV-1 infection in certain patients. Here are the top 7 facts to know about Odefsey.